Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom.
The latest earnings season, spanning late July and early August 2025, has painted a vivid picture of a bifurcated market, where the titans of technology continue to defy gravity, largely propelled by their aggressive and strategic investments in Artificial Intelligence (AI). While companies like Amazon, Apple, Meta, and Microsoft reported
The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors grappling with mixed signals and heightened uncertainty. While the broader market saw a rebound in early August, driven by
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter’s revenue to be around $580 million, close to analysts’ estimates. Its GAAP profit of $0.17 per share was 13% above analysts’ consensus estimates.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
